Loading...
01/10 00:30
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presented strong financial metrics, including raised revenue and EPS guidance, which are positive indicators. The Q&A highlighted positive developments such as strategic partnerships and promising drug trials, with limited negative sentiment from analysts. Despite some hurdles like entrenched prescribing behaviors, the overall sentiment and strategic advancements suggest a positive outlook for the stock price.
Total company revenues Approximately $12.3 billion, reflecting strong demand across the business. Global sales of the growth portfolio increased approximately 17%, driven primarily by demand for the IO portfolio, Breyanzi, Reblozyl, and Camzyos.
Opdivo global sales Approximately $2.6 billion, up 7%, driven primarily by demand. U.S. revenues were approximately $1.5 billion, driven by a strong launch in MSI-high colorectal cancer and growth in first-line non-small cell lung cancer. Outside the U.S., revenues grew 7%, driven by volume growth and one-time favorable adjustments.
Qvantig sales Approximately $30 million. The launch in the U.S. is going well with use across all indicated tumor types. Received a permanent J-Code on July 1, which will support additional conversion as reimbursement improves.
Reblozyl global sales $568 million in the quarter and over $1 billion year-to-date, reflecting continued strength across MDS-associated anemia indications. U.S. revenue growth was up 30% versus the prior year, primarily due to demand growth in first-line RS positive and RS-negative MDS-associated anemia. Outside the U.S., sales grew 46%, driven by demand across newly launched markets.
Breyanzi revenues $344 million in the quarter. Global revenues grew 122%, reflecting strong demand across all indications and higher-than-expected infusions. U.S. sales were $255 million, more than doubling, reflecting growth in large B-cell lymphoma and expansion from new indications. Outside the U.S., sales were $88 million, nearly tripling due to strong demand and launches in new markets.
Camzyos global sales $260 million, growing 86% due to robust demand. U.S. sales were $214 million, up 65%, driven by increasing new patient starts. Outside the U.S., sales were $46 million, reflecting launch momentum in over 20 markets.
Eliquis global sales $3.7 billion, growing 6%, primarily due to strong demand. U.S. sales grew 4%, and ex-U.S. sales grew 12%.
Sotyktu sales Grew 29% globally. U.S. sales increased 5%, primarily due to higher demand and an inventory build, partially offset by higher rebates associated with increased commercial coverage.
Cobenfy sales $35 million in the quarter and $62 million year-to-date. Weekly total prescriptions continued to grow, and steady growth is expected in the second half of the year.
Gross margin Approximately 73%, primarily due to product mix.
Operating expenses Approximately $260 million lower compared to the same period last year, primarily reflecting the results of ongoing strategic productivity initiatives.
Cash flow from operations About $3.9 billion in the second quarter.
Cobenfy: Strong performance since launch with positive feedback from physicians. Demonstrates robust efficacy on both positive and negative symptoms and improved cognition.
Qvantig: Early feedback is encouraging with strong uptake. Offers treatment in just 3 minutes, improving clinic efficiency and patient comfort.
Opdivo: Secured approval in Europe for neoadjuvant lung cancer and multiple solid tumor indications. U.S. FDA streamlined patient monitoring requirements for cell therapies.
BioNTech partnership: Global strategic partnership to co-develop and commercialize BNT327, a PD-L1 VEGF bispecific for multiple tumor types.
Philochem partnership: License agreement for OncoACP3, a radiopharmaceutical therapeutic and diagnostic agent for prostate cancer.
Revenue growth: Total company revenues reached $12.3 billion, with a 17% increase in the growth portfolio driven by demand for key brands.
Cost optimization: Operating expenses reduced by $260 million compared to the previous year due to strategic productivity initiatives.
Immunology focus: Out-licensed 5 assets to a new company formed with Bain Capital, focusing on advancing innovative immunology therapies while retaining a 20% equity stake.
Pipeline investments: Prioritizing high-value assets with multiple ongoing registrational trials in oncology, immunology, and other areas.
Regulatory Challenges: The company faces regulatory challenges, including the need to secure approvals for new drugs and therapies across different regions. While progress has been made, such as FDA streamlining patient monitoring requirements, regulatory hurdles remain a potential risk to timely market entry and revenue generation.
Pipeline Risks: The company acknowledged that some studies in their pipeline did not yield expected results. This raises concerns about the reliability of future data readouts and the potential for delays or failures in bringing new drugs to market.
Market Competition: The company faces intense competition in the immuno-oncology and radiopharmaceutical spaces. The success of partnerships like those with BioNTech and Philochem depends on the ability to outpace competitors in innovation and market entry.
Supply Chain and Manufacturing: While not explicitly mentioned, the company's reliance on manufacturing success rates, particularly for products like Breyanzi, indicates potential vulnerabilities in supply chain and production capabilities.
Financial Risks: The company has increased its operating expense guidance due to investments in business development and growth portfolios. This could strain financial resources if expected returns on these investments are not realized.
Legacy Portfolio Decline: The legacy portfolio is expected to decline by 15% to 17% for the year, which could impact overall revenue growth despite strong performance in the growth portfolio.
Strategic Execution Risks: The company is undergoing significant strategic shifts, including partnerships and pipeline prioritization. Missteps in execution could hinder long-term growth objectives.
Revenue Guidance: The company has increased its full-year revenue guidance to a range of $46.5 billion to $47.5 billion, reflecting strong performance of the growth portfolio, better-than-expected legacy sales, and a favorable foreign exchange impact of approximately $200 million.
Legacy Portfolio Decline: The legacy portfolio is now expected to decline by 15% to 17% for the year, a more moderate rate than previously anticipated due to Revlimid's strong year-to-date performance. Full-year Revlimid sales are projected to be approximately $3 billion.
Operating Expenses: Operating expenses are expected to increase slightly to approximately $16.5 billion, reflecting investments in recent business development deals and additional opportunities within the growth portfolio. Operating expenses are anticipated to be higher in the second half of the year.
Non-GAAP EPS Guidance: The company has updated its 2025 non-GAAP EPS guidance to a range of $6.35 to $6.65, reflecting strong growth portfolio performance, better-than-expected legacy sales, and recent business development investments.
Pipeline and Data Catalysts: The company expects 7 registration assets and 7 meaningful life cycle management opportunities over the next 12 to 24 months. Key data readouts include milvexian in acute coronary syndrome and secondary stroke prevention (2026), admilparant for idiopathic pulmonary fibrosis (2026), and iberdomide for multiple myeloma (2025-2026).
Product Launches and Growth: Recent launches of Cobenfy and Qvantig are progressing well. Cobenfy is expected to see continued steady growth, with second-half sales higher than the first half. Qvantig's U.S. launch has shown strong uptake, and global Opdivo sales combined with Qvantig are expected to grow in the mid- to high single-digit range for the full year.
Strategic Partnerships: The company has entered into a global strategic partnership with BioNTech to co-develop and commercialize BNT327, a potentially transformative PD-L1 VEGF bispecific therapy. Additionally, a license agreement with Philochem for OncoACP3 aims to strengthen the radiopharmaceutical business.
Immunology and Oncology Investments: The company is prioritizing investments in immunology and oncology, including pivotal trials for BNT327 in various cancers and next-generation platforms like PRMT5 inhibitors and EGFR HER3 targeting ADC Iza-bren.
Dividend Commitment: The company remains committed to returning capital to shareholders through its dividend program.
The earnings call showed mixed signals. Financial performance is stable, with steady revenue and strong cash reserves. However, concerns about operational risks in the DRC, high logistics costs, and regulatory risks temper optimism. The Q&A session reveals ongoing challenges in securing offtake agreements and operational uncertainties. Although strategic partnerships and product launches are positive, the lack of clear guidance in some areas leads to a neutral outlook, with potential fluctuations in stock price remaining within a narrow range.
The earnings call summary shows strong financial performance, increased revenue guidance, strategic partnerships, and promising product developments. The Q&A section supports this with positive updates on Cobenfy's commercial progress and strategic partnerships. Although management avoided some questions, the overall sentiment remains positive due to strong growth outlook and strategic initiatives.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
